Previous 10 | Next 10 |
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time...
Summary Today we take our first look at Apellis Pharmaceuticals, a midcap concern with an advancing pipeline. Its flagship product was rolled out last year, is pursuing other indications, and could eventually achieve blockbuster status. However, some insiders are selling and q...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura ® ), an investigational complement C5 inhibitor being evaluate...
The following slide deck was published by IVERIC bio, Inc. in conjunction with this event. For further details see: Developing Transformative Therapies for Retinal Diseases
Shares of Iveric Bio (NASDAQ: ISEE) were skyrocketing 85.9% this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The big gain came after the company announced positive topline results on Tuesday from a late-stage clinic...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor conferences in September: Wells Fargo 2022 Healthcare Conference Da...
Summary Positive results achieved in both GATHER1 and GATHER2 studies, whereby Zimura met prespecified primary endpoints of Mean rate of GA growth compared to sham control with statistical significance. NDA filing of Zimura for the treatment of patients with Geographic Atrophy are...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “IVERIC bio, Inc. Shares Soar Amid Positive Zimura Trial Resultsl” IVERIC bio, Inc. (NASDAQ: ISEE) announced positive topline results from GATHER2, the Co...
Iveric bio ( NASDAQ: ISEE ), have sparked volatility in rival biotechs on Tuesday after the clinical-stage company announced results from a Phase 3 trial for Zimura involving patients with eye disease geographic atrophy (GA) secondary to dry age- related macular degeneration...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock / PopTika Iveric Bio (NASDAQ: ISEE ) stock is rising higher on Tuesday after the biopharmaceutical company revealed positive results from a Phase 3 clinical trial . That trial covered the...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...